Expertise in
3
conditions

Junichiro Yuda

Kashiwa, JP 
Expertise in
3
conditions
Kashiwa, JP 

Overview

Junichiro Yuda practices practicing medicine in Kashiwa, Japan.

Yuda is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Leukemia, Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), B-Cell Lymphoma, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 53 peer reviewed articles and participating in 2 clinical trials.

Locations

Kashiwa, Japan
Other Locations
Chiba, Japan
Fukuoka, 8128582, Japan
Japan
Yamagata, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Rituximab
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

53 Total Publications

AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC.
AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC.
Journal: International journal of clinical oncology
Published: June 14, 2026

Frequently Asked Questions about Junichiro Yuda

Is Junichiro Yuda a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Junichiro Yuda is classified as an Advanced expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Junichiro Yuda participate in research or clinical trials?

Yes. Junichiro Yuda has published 53 articles and abstracts on conditions like Leukemia. You can view a list of Junichiro Yuda's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yuda's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile